Agent for controlling cells constituting cancer microenvironment or inflammatory microenvironment

Abstract

An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Divisional application of co-pending application Ser. No. 15 / 542,028, filed on Aug. 8, 2017, which is the National Phase under 35 U.S.C. § 371 of International Application No. PCT / JP2016 / 050214, filed on Jan. 6, 2016, which claims the benefit under 35 U.S.C. § 119(a) to Patent Application No. 2015-000978, filed in Japan on Jan. 6, 2015, all of which are hereby expressly incorporated by reference into the present application.TECHNICAL FIELD[0002]The present invention relates to a novel FROUNT protein inhibitor, and control of cells constituting a cancer microenvironment or inflammatory microenvironment using the inhibitor.BACKGROUND ART[0003]FROUNT protein is a cytoplasmic protein that binds to the intracellular C-terminal regions of chemokine receptors CCR2 and CCR5, and positively controls migration signals of macrophages and the like (Patent Document 1, Non-patent Documents 1 and 2). This protein is a novel molecul...

AI Technical Summary

Benefits of technology

The present invention provides a new agent that can inhibit cancer cells and reduce the accumulation of microenvironment-constituting cells, like macrophages, which can promote cancer growth and metastasis. This agent specifically targets the microenvironment around cancer cells, and can be used in combination with other anticancer drugs to increase their effectiveness and reduce side effects. Additionally, the invention provides a disulfiram derivative that has lower side effects and increased pharmacological effects, making it a potential treatment for alcoholism and other inflammatory diseases.

Problems solved by technology

However, none of these attempts has been successful.

Thus, after taking of disulfiram, symptoms of sickness caused by drinking occur even with a small amount of alcohol.

However, actions of disulfiram on microenvironment-constituting cells such as immune cells, fibroblasts, vascular endothelial cells and the like present in the vicinity of cancer cells have not been known at all.

Images